What is your approach for adjuvant endocrine therapy in a female with HR+ breast cancer with history of provoked DVT while on OCPs?

In a postmenopausal female with HR+HER2- breast cancer and a history of DVT on OCPs, I would recommend adjuvant endocrine therapy with an aromatase inhibitor and not tamoxifen. This is based on improved efficacy for aromatase inhibitors compared to tamoxifen in this population, and VTE risk associat...